کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5985175 | 1178771 | 2016 | 12 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States](/preview/png/5985175.png)
- Study assessed real-world statins in CHD and CHD RE patients using new guidelines.
- Statin use increased at 1-year follow-up; most received a moderate-intensity statin.
- 38.7% (CHD) and 44.3% (CHD RE) patients with CV event did not have a statin claim.
- LDL-C ⥠100 mg/dL was seen in 29.3% (CHD) and 30% (CHD RE) patients with a CV event.
- 9.9% (CHD) and 7.3% (CHD RE) patients had at least one CV event at 1 year follow-up MI (CHD) and stroke (CHD RE) were the most commonly observed CV events.
BackgroundStatins have demonstrated significant benefit in reducing cardiovascular disease (CVD) risk.ObjectiveTo evaluate statin treatment patterns by intensity, elevated low-density lipoprotein cholesterol (LDL-C) levels, and cardiovascular (CV) events in high-risk CVD patients.MethodsPatients included were aged â¥18 years, with a coronary heart disease (CHD; Jan 1, 2007-Dec 31, 2011, index date) or CHD risk equivalent (CHD RE) diagnosis (Jan 1, 2007-Dec 31, 2010, index date), in the Truven MarketScan claims database, continuously enrolled for 2 years pre- and up to 1 (CHD) or 2 (CHD RE) years post-index. Patients with CHD, CHD RE, rhabdomyolysis, or chronic kidney disease any time pre-index were excluded. Statin therapy was assessed at baseline, 30, 90, and 365 days post-index. LDL-C values were captured in patients with available data at 30-day intervals up to 1 year. CV events were evaluated up to 1 year post-index. Descriptive statistics were used to report results.ResultsThere were 175,103 CHD and 68,290 CHD RE patients; 3333 CHD RE patients had post-index CV events. At 1 year, 38.7% of CHD patients and 44.3% of CHD RE patients with post-index CV events were not prescribed statins. Most patients who were prescribed statins, received a moderate-intensity statin. The percentage of patients with LDL-C ⥠100 mg/dL reduced over time, but at 1 year, 29.3% of CHD and 30.0% of CHD RE patients with post-index CV events had LDL-C ⥠100 mg/dL. At 1 year post-index, 9.9% CHD and 7.3% CHD RE patients had at least 1 CV event.ConclusionThere is room for better LDL-C management among high-risk CVD patients to reduce their overall CV risk.
Journal: Journal of Clinical Lipidology - Volume 10, Issue 1, JanuaryâFebruary 2016, Pages 63-71.e3